^
Association details:
| Biomarker: | EML4-ALK fusion |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
Published date:
10/09/2021
Excerpt:
There were eight patients with EGFR-mutant LUSC (median age = 58 y) and six patients with EML4-ALK LUSC (median age = 50 y) who received tyrosine kinase inhibitors (TKIs) that were identified….With TKI treatment, seven of eight cases of EGFR LUSC and four of six cases of ALK LUSC achieved partial response or stable disease, but the progression-free survival was 4.9 months and 2.9 months for EGFR-mutant and ALK-rearranged LUSC, respectively.
DOI:
10.1016/j.jtocrr.2021.100237
